FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023376583> ?p ?o ?g. }

• W2023376583 endingPage "1057" @default.
• W2023376583 startingPage "1051" @default.
• W2023376583 abstract "Patients with follicular lymphoma (FL) typically experience an indolent course; however, the disease is rarely curable with conventional chemotherapy. Autologous hematopoietic cell transplantation (HCT) can extend progression-free survival (PFS) and overall survival (OS), but relapse is the primary cause of failure. Allogeneic HCT confers lower relapse rates due to a graft-versus-lymphoma effect. Reduced-intensity conditioning (RIC) allows the performance of allogeneic HCT with lower toxicity. The Blood and Marrow Transplant Clinical Trials Network conducted a prospective multicenter trial comparing these two strategies in patients with relapsed, chemotherapy-sensitive FL. Patients were assigned to a treatment arm based on the availability of an HLA-matched sibling donor (MSD). Those with an MSD underwent allogeneic HCT (n = 8) with the FCR preparative regimen (fludarabine, cyclophosphamide [Cy], rituximab [RTX]) and received tacrolimus and methotrexate for graft-versus-host disease (GVHD) prophylaxis. Those without an MSD (n = 22) underwent mobilization with Cy, RTX, and filgrastim and received a conditioning regimen of either CBV (Cy, carmustine, Etoposide [VP16]) or total body irradiation with Cy and VP16. Patients undergoing autologous HCT received 4 doses of weekly maintenance RTX (375 mg/m2) starting on day +42 post-HCT. Sixteen patients were in complete remission, 10 patients were in partial remission, and 1 patient had stable disease after salvage therapy and before HCT. Median follow-up was 36 months (range, 1-51 months). OS was 73% in autologous HCT versus 100% in allogeneic HCT, and PFS was 63% in autologous HCT versus 86% in allogeneic HCT. No patient had grade II-IV acute GVHD; two patients developed extensive chronic GVHD. Three autologous recipients died from nonrelapse causes. This trial closed early because of slow accrual. We show that the FCR regimen is well tolerated, and that both allogeneic and autologous HCT result in promising 3-year OS and PFS in patients with relapsed FL. Patients with follicular lymphoma (FL) typically experience an indolent course; however, the disease is rarely curable with conventional chemotherapy. Autologous hematopoietic cell transplantation (HCT) can extend progression-free survival (PFS) and overall survival (OS), but relapse is the primary cause of failure. Allogeneic HCT confers lower relapse rates due to a graft-versus-lymphoma effect. Reduced-intensity conditioning (RIC) allows the performance of allogeneic HCT with lower toxicity. The Blood and Marrow Transplant Clinical Trials Network conducted a prospective multicenter trial comparing these two strategies in patients with relapsed, chemotherapy-sensitive FL. Patients were assigned to a treatment arm based on the availability of an HLA-matched sibling donor (MSD). Those with an MSD underwent allogeneic HCT (n = 8) with the FCR preparative regimen (fludarabine, cyclophosphamide [Cy], rituximab [RTX]) and received tacrolimus and methotrexate for graft-versus-host disease (GVHD) prophylaxis. Those without an MSD (n = 22) underwent mobilization with Cy, RTX, and filgrastim and received a conditioning regimen of either CBV (Cy, carmustine, Etoposide [VP16]) or total body irradiation with Cy and VP16. Patients undergoing autologous HCT received 4 doses of weekly maintenance RTX (375 mg/m2) starting on day +42 post-HCT. Sixteen patients were in complete remission, 10 patients were in partial remission, and 1 patient had stable disease after salvage therapy and before HCT. Median follow-up was 36 months (range, 1-51 months). OS was 73% in autologous HCT versus 100% in allogeneic HCT, and PFS was 63% in autologous HCT versus 86% in allogeneic HCT. No patient had grade II-IV acute GVHD; two patients developed extensive chronic GVHD. Three autologous recipients died from nonrelapse causes. This trial closed early because of slow accrual. We show that the FCR regimen is well tolerated, and that both allogeneic and autologous HCT result in promising 3-year OS and PFS in patients with relapsed FL." @default.
• W2023376583 created "2016-06-24" @default.
• W2023376583 creator A5005492422 @default.
• W2023376583 creator A5008575399 @default.
• W2023376583 creator A5010176911 @default.
• W2023376583 creator A5036425755 @default.
• W2023376583 creator A5040683449 @default.
• W2023376583 creator A5069054551 @default.
• W2023376583 creator A5070553243 @default.
• W2023376583 creator A5080373697 @default.
• W2023376583 creator A5091433944 @default.
• W2023376583 date "2011-07-01" @default.
• W2023376583 modified "2023-10-18" @default.
• W2023376583 title "Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond First Complete Response or First Partial Response" @default.
• W2023376583 cites W1912693401 @default.
• W2023376583 cites W1978544728 @default.
• W2023376583 cites W2001851267 @default.
• W2023376583 cites W2019131761 @default.
• W2023376583 cites W2020551482 @default.
• W2023376583 cites W2037252592 @default.
• W2023376583 cites W2039845134 @default.
• W2023376583 cites W2050171635 @default.
• W2023376583 cites W2058887761 @default.
• W2023376583 cites W2064714453 @default.
• W2023376583 cites W2080314536 @default.
• W2023376583 cites W2085947607 @default.
• W2023376583 cites W2097470232 @default.
• W2023376583 cites W2098901377 @default.
• W2023376583 cites W2099156781 @default.
• W2023376583 cites W2105397991 @default.
• W2023376583 cites W2107202569 @default.
• W2023376583 cites W2118565886 @default.
• W2023376583 cites W2131904409 @default.
• W2023376583 cites W2138881579 @default.
• W2023376583 cites W2150748222 @default.
• W2023376583 cites W2152264545 @default.
• W2023376583 cites W2153859516 @default.
• W2023376583 cites W2162489923 @default.
• W2023376583 cites W2338573834 @default.
• W2023376583 cites W2583932433 @default.
• W2023376583 cites W2618073389 @default.
• W2023376583 cites W329934425 @default.
• W2023376583 cites W4293241248 @default.
• W2023376583 doi "https://doi.org/10.1016/j.bbmt.2010.11.004" @default.
• W2023376583 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3114272" @default.
• W2023376583 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21073974" @default.
• W2023376583 hasPublicationYear "2011" @default.
• W2023376583 type Work @default.
• W2023376583 sameAs 2023376583 @default.
• W2023376583 citedByCount "72" @default.
• W2023376583 countsByYear W20233765832012 @default.
• W2023376583 countsByYear W20233765832013 @default.
• W2023376583 countsByYear W20233765832014 @default.
• W2023376583 countsByYear W20233765832015 @default.
• W2023376583 countsByYear W20233765832016 @default.
• W2023376583 countsByYear W20233765832017 @default.
• W2023376583 countsByYear W20233765832018 @default.
• W2023376583 countsByYear W20233765832019 @default.
• W2023376583 countsByYear W20233765832020 @default.
• W2023376583 countsByYear W20233765832021 @default.
• W2023376583 countsByYear W20233765832022 @default.
• W2023376583 crossrefType "journal-article" @default.
• W2023376583 hasAuthorship W2023376583A5005492422 @default.
• W2023376583 hasAuthorship W2023376583A5008575399 @default.
• W2023376583 hasAuthorship W2023376583A5010176911 @default.
• W2023376583 hasAuthorship W2023376583A5036425755 @default.
• W2023376583 hasAuthorship W2023376583A5040683449 @default.
• W2023376583 hasAuthorship W2023376583A5069054551 @default.
• W2023376583 hasAuthorship W2023376583A5070553243 @default.
• W2023376583 hasAuthorship W2023376583A5080373697 @default.
• W2023376583 hasAuthorship W2023376583A5091433944 @default.
• W2023376583 hasBestOaLocation W20233765831 @default.
• W2023376583 hasConcept C126322002 @default.
• W2023376583 hasConcept C141071460 @default.
• W2023376583 hasConcept C143998085 @default.
• W2023376583 hasConcept C2776694085 @default.
• W2023376583 hasConcept C2776755627 @default.
• W2023376583 hasConcept C2777058707 @default.
• W2023376583 hasConcept C2778119113 @default.
• W2023376583 hasConcept C2778880498 @default.
• W2023376583 hasConcept C2779263901 @default.
• W2023376583 hasConcept C2779338263 @default.
• W2023376583 hasConcept C2780147359 @default.
• W2023376583 hasConcept C2780653079 @default.
• W2023376583 hasConcept C2781413609 @default.
• W2023376583 hasConcept C2911091166 @default.
• W2023376583 hasConcept C71924100 @default.
• W2023376583 hasConcept C90924648 @default.
• W2023376583 hasConceptScore W2023376583C126322002 @default.
• W2023376583 hasConceptScore W2023376583C141071460 @default.
• W2023376583 hasConceptScore W2023376583C143998085 @default.
• W2023376583 hasConceptScore W2023376583C2776694085 @default.
• W2023376583 hasConceptScore W2023376583C2776755627 @default.
• W2023376583 hasConceptScore W2023376583C2777058707 @default.
• W2023376583 hasConceptScore W2023376583C2778119113 @default.
• W2023376583 hasConceptScore W2023376583C2778880498 @default.
• W2023376583 hasConceptScore W2023376583C2779263901 @default.
• W2023376583 hasConceptScore W2023376583C2779338263 @default.

• next